ストックスクリーナーアプリを入手
47.68
2.72%
-1.21
前日終値:
$48.89
開ける：
$48.7
24時間の取引高:
344.38K
Relative Volume:
0.66
時価総額：
$2.92B
収益：
-
当期純損益:
$-145.21M
株価収益率:
-20.73
EPS:
-2.3
ネットキャッシュフロー:
$-140.12M
1週間 パフォーマンス:
+0.76%
1か月 パフォーマンス:
+1.45%
6か月 パフォーマンス:
-5.28%
1年 パフォーマンス:
+13.16%
1日の値動き範囲:
$46.86
$49.15
1週間の範囲:
$46.24
$49.29
52週間の値動き範囲:
$31.42
$58.26
Moonlake Immunotherapeutics Stock (MLTX) Company Profile
MLTX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
MLTX
Moonlake Immunotherapeutics
|
47.64 | 2.92B | 0 | -145.21M | -140.12M | -2.30 |
|
VRTX
Vertex Pharmaceuticals Inc
|
459.76 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
537.58 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
323.00 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
543.65 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
241.30 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Moonlake Immunotherapeutics Stock (MLTX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-05-19 | アップグレード | Wolfe Research | Peer Perform → Outperform |
| 2025-03-18 | 開始されました | RBC Capital Mkts | Outperform |
| 2025-01-17 | アップグレード | Goldman | Neutral → Buy |
| 2024-11-05 | 再開されました | Wedbush | Outperform |
| 2024-08-26 | ダウングレード | Wolfe Research | Outperform → Peer Perform |
| 2024-06-25 | 開始されました | Oppenheimer | Outperform |
| 2024-04-02 | 開始されました | Goldman | Neutral |
| 2024-02-15 | 開始されました | Wolfe Research | Outperform |
| 2023-12-08 | 開始されました | Citigroup | Buy |
| 2023-11-02 | 開始されました | Stifel | Buy |
| 2023-09-14 | ダウングレード | Bryan Garnier | Buy → Neutral |
| 2023-08-31 | 開始されました | Needham | Buy |
| 2023-06-15 | 開始されました | Barclays | Equal Weight |
| 2023-05-01 | 開始されました | Guggenheim | Buy |
| 2023-03-22 | 開始されました | Wedbush | Outperform |
| 2023-03-09 | 開始されました | BTIG Research | Buy |
| 2023-02-14 | 開始されました | Cantor Fitzgerald | Overweight |
| 2023-02-02 | 開始されました | Bryan Garnier | Buy |
| 2022-11-11 | 開始されました | Jefferies | Buy |
| 2022-08-25 | 開始されました | SVB Leerink | Outperform |
| 2022-07-21 | 開始されました | H.C. Wainwright | Buy |
| 2022-07-07 | 開始されました | Cowen | Outperform |
すべてを表示
Moonlake Immunotherapeutics (MLTX) 最新ニュース
Merck Offers Over $3 Billion to Acquire MoonLake Immunotherapeutics Amid Biotech Sector Challenges - geneonline.com
Merck Offers Over $3 Billion to Acquire MoonLake Immunotherapeutics Amid Biotech Sector Developments - geneonline.com
Learn to Evaluate (MLTX) using the Charts - news.stocktradersdaily.com
Merck Offers Over $3 Billion to Acquire MoonLake Immunotherapeutics Amid Industry Developments - geneonline.com
MoonLake Immunotherapeutics’ SWOT analysis: nanobody firm’s stock poised for pivotal phase III data - Investing.com South Africa
Merck's Keytruda Secures FDA Nod For Head And Neck Cancer As First Immunotherapy For Use Around Surgery - Benzinga
IIH interview: Matthias Bodenstedt discusses MoonLake’s capital raising journey, the appeal of SLK and plans for the future - Investors in Healthcare
MoonLake Immunotherapeutics: Strategic Positioning and Promising Clinical Developments Drive Buy Rating - TipRanks
Merck Offers Over $3 Billion to Acquire MoonLake Immunotherapeutics Amid Focus on Inflammatory Disease Treatments - geneonline.com
MoonLake Immunotherapeutics Catapults On Rumored Merck Takeover - MSN
Merck Offers Over $3 Billion to Acquire MoonLake Immunotherapeutics Amid Biotech Sector Focus - geneonline.com
MoonLake Immunotherapeutics (MLTX) Hosts Investor Meetings Amid Merger Speculation | MLTX Stock News - GuruFocus
Stat’s Feuerstein says ‘no imminent acquisition’ of MoonLake Immunotherapeutics - TipRanks
StockWatch: Report of $3B+ Merck Buyout Offer Propels MoonLake Stock Surge - Genetic Engineering and Biotechnology News
MoonLake Immunotherapeutics (NASDAQ:MLTX) Shares Purchased by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC - Defense World
MoonLake Immunotherapeutics Reportedly Exploring Potential Sale Amid Strategic Uncertainty - geneonline.com
MLTX Stock Gains 18% as Merck Reportedly Eyes Buyout - MSN
MoonLake Immunotherapeutics Elects Directors at AGM - TipRanks
Merck held talks to buy biotech MoonLake for over $3 billion - MSN
These Stocks Moved the Most Today: Nvidia, Tesla, Dollar General, Credo, Ferguson, Moonlake, and More - MSN
MoonLake Immunotherapeutics Reportedly Exploring Potential Sale Amid Industry Speculation - geneonline.com
A MoonLake Buyout Would Boost Merck & Co’s Immunology Ambitions - insights.citeline.com
MoonLake Immunotherapeutics Reportedly Considering Sale Amid Competitive Pharmaceutical Market Challenges - geneonline.com
MoonLake Immunotherapeutics is for sale? This sounds like a cry for help - statnews.com
Merck's Bold Proposal Sends MoonLake's Shares Climbing - Finimize
Merck made $3B+ offer for MoonLake earlier this yearreport - MSN
Two Biotechs That Could Get an M&A Boost - TheStreet Pro
Merck & Co., Inc. (MRK) Held Talks Over $3 Billion Acquisition of Swiss Biotech Firm MoonLake - MSN
Merck in Talks to Acquire MoonLake Immunotherapeutics for $3 Billion - geneonline.com
MSD rumoured to be eyeing $3bn+ MoonLake takeover - pharmaphorum
MoonLake Immunotherapeutics (MLTX) Surges 25% on Merck Acquisiti - GuruFocus
MoonLake Immunotherapeutics Catapults On Rumored $3 Billion Merck Takeover Bid - Investor's Business Daily
MoonLake Immunotherapeutics: More Sonelokimab Success, With Big Pharma Interest (MLTX) - Seeking Alpha
Merck Offers Over $3 Billion to Acquire MoonLake Immunotherapeutics Amid Industry Shifts - geneonline.com
MoonLake Immunotherapeutics Breaks Above 200-Day Moving AverageBullish for MLTX - Nasdaq
MoonLake's (MLTX) 'Outperform' Rating Reiterated by RBC Capital - GuruFocus
MoonLake takeover thesis reemerges after FT report, says Citi - TipRanks
MoonLake Shares Jump On Potential Merck Acquisition Offer - Finimize
MoonLake Immunotherapeutics: Strong Acquisition Interest and Promising Product Pipeline Drive Buy Rating - TipRanks
RBC Capital maintains outperform rating on Moonlake stock By Investing.com - Investing.com India
RBC Capital maintains outperform rating on Moonlake stock - Investing.com
Moonlake Immunotherapeutics (MLTX) 財務データ
収益
当期純利益
現金流量
EPS
Moonlake Immunotherapeutics (MLTX) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| BVF PARTNERS L P/IL | Director |
Oct 04 '24 |
Sale |
50.00 |
2,000,000 |
100,003,200 |
1,287,768 |
| Sturge Simon | Director |
Oct 04 '24 |
Sale |
53.72 |
171,000 |
9,186,120 |
171,980 |
0.84%
0.47%
大文字化:
|
ボリューム (24 時間):